Convergent Synthesis of Two Fluorescent Ebselen-Coumarin Heterodimers
AbstractThe organo-seleniumdrug ebselen exhibits a wide range of pharmacological effects that are predominantly due to its interference with redox systems catalyzed by seleno enzymes, e.g., glutathione peroxidase and thioredoxin reductase. Moreover, ebselen can covalently interact with thiol groups of several enzymes. According to its pleiotropic mode of action, ebselen has been investigated in clinical trials for the prevention and treatment of different ailments. Fluorescence-labeled probes containing ebselen are expected to be suitable for further biological and medicinal studies. We therefore designed and synthesized two coumarin-tagged activity-based probes bearing the ebselen warhead. The heterodimers differ by the nature of the spacer structure, for which—in the second compound—a PEG/two-amide spacer was introduced. The interaction of this probe and of ebselen with two cysteine proteases was investigated. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 1855 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Küppers, J.; Schulz-Fincke, A.C.; Palus, J.; Giurg, M.; Skarżewski, J.; Gütschow, M. Convergent Synthesis of Two Fluorescent Ebselen-Coumarin Heterodimers. Pharmaceuticals 2016, 9, 43.
Küppers J, Schulz-Fincke AC, Palus J, Giurg M, Skarżewski J, Gütschow M. Convergent Synthesis of Two Fluorescent Ebselen-Coumarin Heterodimers. Pharmaceuticals. 2016; 9(3):43.Chicago/Turabian Style
Küppers, Jim; Schulz-Fincke, Anna C.; Palus, Jerzy; Giurg, Mirosław; Skarżewski, Jacek; Gütschow, Michael. 2016. "Convergent Synthesis of Two Fluorescent Ebselen-Coumarin Heterodimers." Pharmaceuticals 9, no. 3: 43.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.